A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

MC #21-28

Molecular Target(s)
Drug Classification(s)
conditionally active biologic (CAB) anti-AXL humanized monoclonal antibody
BA3011 (mecbotamab vedotin) and Nivolumab

Mechanism of Action

BA3011, an anti-AXL antibody, is designed to have pH-sensitive binding to restrict its activity to the typically acidic tumor microenvironment. The Antibody target is AXL, a transmembrane that may be overexpressed in Non-Small Cell Lung Cancer.


  • About the safety and tolerability of the study agent alone or in combination with Nivolumab
  • How the study agent works with and without Nivolumab in fighting cancer cells (particularly in participants with sarcomas)
  • How proteins that indicate the status of your disease are affected with the use of the study agent
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If your body develops proteins that work against the study agent
  • If research tests can be used in the future to predict who will benefit from BA3011
  • If the study agent alone or in combination with Nivolumab prevents or delays tumor growth



Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.